Explore more publications!
Guinea Bissau Health Bulletin
Got News to Share?

Guinea Bissau Health Bulletin: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on October 20, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
October 20, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Indeterminate GlobeNewswire
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
October 20, 2025

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Indeterminate GlobeNewswire
OGRD Alliance Expands OncoVix and PLPC-DB Initiatives from the Emirates to Asia and MENA Regions
October 20, 2025

OGRD Alliance Expands OncoVix and PLPC-DB Initiatives from the Emirates to Asia and MENA Regions

Indeterminate GlobeNewswire
Kraig Biocraft Laboratories Launches Its Sixth 2025 Spider Silk Production Cycle, Introducing the Next Evolution of Its BAM-1 Alpha Recombinant Silk Platform
October 20, 2025

Kraig Biocraft Laboratories Launches Its Sixth 2025 Spider Silk Production Cycle, Introducing the Next Evolution of Its BAM-1 Alpha Recombinant Silk Platform

Indeterminate GlobeNewswire
Humber River Health Celebrates 10-Year Anniversary of Wilson Site
October 20, 2025

Humber River Health Celebrates 10-Year Anniversary of Wilson Site

Indeterminate GlobeNewswire
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
October 20, 2025

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Indeterminate GlobeNewswire
Medicenna Therapeutics Announces Participation in Upcoming Conferences
October 20, 2025

Medicenna Therapeutics Announces Participation in Upcoming Conferences

Indeterminate GlobeNewswire
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
October 20, 2025

BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease

Indeterminate GlobeNewswire
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
October 20, 2025

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Indeterminate GlobeNewswire
Kratom Products for Energy and Balance: Kratom Bird Expands Its Collection in 2025
October 20, 2025

Kratom Products for Energy and Balance: Kratom Bird Expands Its Collection in 2025

Indeterminate GlobeNewswire
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
October 20, 2025

RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call

Indeterminate GlobeNewswire
The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025
October 20, 2025

The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025

Indeterminate GlobeNewswire
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
October 20, 2025

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Indeterminate GlobeNewswire
Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025
October 20, 2025

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025

Indeterminate GlobeNewswire
Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million
October 20, 2025

Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million

Indeterminate GlobeNewswire
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
October 20, 2025

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Indeterminate GlobeNewswire
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
October 20, 2025

ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors

Indeterminate GlobeNewswire
Medela AG Introduces the New Motion InBra™ Wearable Breast Pump – Where Dependable Performance Meets Everyday Comfort
October 20, 2025

Medela AG Introduces the New Motion InBra™ Wearable Breast Pump – Where Dependable Performance Meets Everyday Comfort

Indeterminate GlobeNewswire
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
October 20, 2025

Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)

Indeterminate GlobeNewswire
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions